Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, et al. A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clin Cancer Res 2022;28:893-902.
PMID: 34921023